Program
astegolimab
Also written as “Astegolimab”, “MSTT1041A” and “AMG 282”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma · Dermatitis, Atopic · COVID-19 · Nasal Polyps, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 71 open or running | phase 3since Oct 24, 2022 | Sep 27, 2016 | Jun 30, 2027phase 3 · NCT05878769 |
| Amgen | 20 open or running | phase 1since Aug 21, 2013 | Aug 21, 2013 | none ahead |
- Named in Hoffmann-La Roche’s own pipeline as
RG6149 astegolimab
, phase 3, as of Oct 22, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 21, 2013First study: phase 1 study in AsthmaNew to AmgenAmgen · NCT01928368 · 70 enrolled · United States
- Jun 19, 2014Phase 1 study in Chronic Rhinosinusitis With Nasal PolypsAmgen · NCT02170337 · 41 enrolled · United States
- Sep 27, 2016Hoffmann-La Roche's first study: phase 2 study in AsthmaNew to Hoffmann-La RocheHoffmann-La Roche · NCT02918019 · 517 enrolled · United States, Argentina, Belgium and more
- Nov 16, 2018Phase 2 study in Dermatitis, AtopicHoffmann-La Roche · NCT03747575 · 65 enrolled · United States, Germany, Poland
- May 11, 2020Phase 2 study in COVID-19 PneumoniaHoffmann-La Roche · NCT04386616 · 396 enrolled · United States, Brazil, Mexico and more
- Aug 31, 2021Phase 2 study in Pulmonary Disease, Chronic ObstructiveHoffmann-La Roche · NCT05037929 · 1,334 enrolled · United States, Argentina, Australia and more
- Oct 24, 2022Phase 3 study in Pulmonary Disease, Chronic ObstructiveHoffmann-La Roche · NCT05595642 · 1,380 enrolled · United States, Argentina, Australia and more
- May 19, 2023Phase 3 study in Pulmonary Disease, Chronic ObstructiveHoffmann-La Roche · NCT05878769 · 2,000 enrolled · United States, Argentina, Australia and more
- Jun 12, 2024Phase 1 study in Healthy VolunteersHoffmann-La Roche · NCT06462118 · 78 enrolled · United States
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveHoffmann-La Roche · NCT05878769
TargetBeta
“A human monoclonal antibody directed against ST2, a receptor for the human inflammatory cytokine interleukin-33 (IL-33), with potential anti-inflammatory activity. Upon administration, astegolimab targets and binds to ST2. This prevents the binding of IL-33 to its receptor complex ST2 (IL1RL1) an…”NCIt, read by Claude
Other programs on IL33R
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| TQC2938 | Sino Biopharmaceutical | phase 2 | 3 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06462118Healthy Volunteers · United States | 1 | Completed | Hoffmann-La Roche | Oct 22, 2024 | 78 |
| NCT05878769Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2027 | 2,000 |
| NCT05595642Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Jun 24, 2025 | 1,380 |
| NCT05037929Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 2 | Completed | Hoffmann-La Roche | Feb 24, 2025 | 1,334 |
| NCT04386616COVID-19 Pneumonia · United States, Brazil, Mexico and more | 2 | Completed | Hoffmann-La Roche | Jan 8, 2021 | 396 |
| NCT03747575Dermatitis, Atopic · United States, Germany, Poland | 2 | Completed | Hoffmann-La Roche | Mar 11, 2020 | 65 |
| NCT02918019Asthma · United States, Argentina, Belgium and more | 2 | Completed | Hoffmann-La Roche | Apr 5, 2019 | 517 |
| NCT02170337Chronic Rhinosinusitis With Nasal Polyps · United States | 1 | Completed | Amgen | May 2016 | 41 |
| NCT01928368Asthma · United States | 1 | Completed | Amgen | Mar 2016 | 70 |
How it is read
Names in the registry
- “Astegolimab”, 4 entries
- “MSTT1041A”, 3 entries
- “AMG 282”, 2 entries
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 3 studies
- Asthma, 2 studies
- Dermatitis, Atopic, 1 study
- COVID-19, 1 study
- Nasal Polyps, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.